GlobeNewswire by notified

Paper in Scientific Reports Highlights Ability of 4D Pharma’s MRx0004 to Protect Against Airway Inflammation in Severe Asthma

Share
  • Data suggest that MRx0004 is a promising next-generation therapeutic for management of asthma

LEEDS, United Kingdom, Aug. 14, 2018 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announces the publication of a paper demonstrating that MRx0004, a live biotherapeutic derived from the human gut microbiome, can protect against airway inflammation by reducing both neutrophilic and eosinophilic infiltration in a mouse model of severe asthma.

The paper “Bifidobacterium breve MRx0004 protects against airway inflammation in a severe asthma model by suppressing both neutrophil and eosinophil lung infiltration” (Raftis et al.) is published in the Nature Publishing Group journal Scientific Reports .

Asthma is a phenotypically heterogeneous disease.  Between 5-10 % of asthma patients have a severe form of the disease which is refractory to steroid treatment and whose symptoms cannot be controlled despite the application of high-intensity treatments.  In severe asthma, airway inflammation can be predominantly eosinophilic, neutrophilic, or mixed and patients presenting with neutrophilic inflammation have particularly poor treatment options.  Severe asthma is estimated to account for more than 60% of asthma-associated healthcare costs.

MRx0004 is a strain of Bifidobacterium breve isolated from the gut microbiome of a healthy human.  It was tested prophylactically and therapeutically in a house dust mite mouse model of severe asthma.  A strong reduction of neutrophil and eosinophil infiltration was observed in lung bronchoalveolar lavage fluid (BALF) following MRx0004 treatment.  Furthermore, MRx0004 had a striking effect on lung histopathology, with a strong reduction of both peribronchiolar and perivascular inflammatory infiltrate. The efficacy of MRx0004 exceeded that of the anti-IL-17 positive control used in the experiment.

4D pharma Chief Scientific Officer, Alex Stevenson, commented, “These data provide further evidence that live biotherapeutics have the potential to change the way we treat disease.  Using MRx0004, we have demonstrated superior efficacy to biologics in a severe and steroid-resistant model of asthma.”

He added, “Perhaps more significantly, we have shown that MRx0004 can strongly reduce neutrophil and eosinophil airway infiltration concurrently.  This is something which is not achievable with current therapies and is further evidence of the potential of MRx0004 as a next-generation therapeutic for the management of asthma.”

For further information please contact:

4D + 44 (0)113 895 0130
Duncan Peyton, Chief Executive Officer  
   
Zeus Capital Limited - Nomad and Joint Broker  
Dan Bate / Jordan Warburton +44 (0) 161 831 1512
   
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500
Dominic Wilson
Phil Walker
 

About 4D
Founded in February 2014, 4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease.  4D has developed a proprietary platform that rationally identifies novel bacteria that have a precise and evolved therapeutic effect.  All of 4D's live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut.  4D has completed a phase I study in Irritable Bowel Syndrome and has completed dosing in a phase I study in Paediatric Crohn's Disease.  It currently has a pipeline of 13 pre-clinical programmes, covering disease areas such as cancer, poorly controlled asthma, autoimmune and CNS disease, and plans to commence four additional clinical studies in 2018. For more information, refer to https://www.4dpharmaplc.com/.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Scatec ASA: Mandatory notification of trade by primary insider19.3.2024 08:24:36 CET | Press release

Oslo, 19 March 2024: Mette Krogsrud, board member of Scatec ASA has on 18 March 2024 bought 2,000 shares in Scatec ASA at an average price per share of NOK 66.50. After the transaction Mette Krogsrud owns 3,000 shares in Scatec ASA. Attached is the notification of the transaction in accordance with the Market Abuse Regulation Article 19. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading act. Attachment Notification of transaction_18032024 KRT- Krogsrud

Boyden Expands Presence in Energy Sector with Acquisition of FWB's Energy Practice in Scotland19.3.2024 08:15:00 CET | Press release

Move marks a significant expansion for Boyden in the energy sector and underscores its commitment to providing unparalleled service to clients worldwide. ABERDEEN, Scotland, March 19, 2024 (GLOBE NEWSWIRE) -- Boyden, the global leadership and talent advisory firm, announces the acquisition of FWB's Energy Practice in Scotland, United Kingdom, effective March 1st, 2024. With this acquisition, Boyden in the United Kingdom will be operating from new offices in Aberdeen, adding to its UK presence in London. The acquisition further strengthens Boyden's industrial practice and enhances its ability to serve clients globally in the oil, gas, mining, and renewables industries. Nick Robeson, Managing Partner for Boyden in the UK & Ireland, expressed his appreciation to the FWB team involved in the acquisition and stated, "We are delighted to have come to an agreement with FWB to acquire their Aberdeen-based Oil, Gas and Energy practice. Boyden's global footprint in Energy was highly attractive t

Equinor ASA: Tilbakekjøp av egne aksjer19.3.2024 08:00:00 CET | Pressemelding

Nedenfor følger informasjon om transaksjoner foretatt under første transje av Equinor ASAs (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO) tilbakekjøpsprogram for 2024. Dato for når første transje av 2024-programmet ble annonsert: 7. februar 2024. Varigheten til første transje av 2024-programmet: 8. februar til senest 5. april 2024. Ytterligere informasjon om transjen kan finnes i børsmelding om dens oppstart datert 7. februar 2024, tilgjengelig her: https://newsweb.oslobors.no/search?issuer=1309 Fra 11. mars til 15. mars 2024, har Equinor ASA kjøpt tilbake totalt 1.845.000 egne aksjer til en gjennomsnittspris på NOK 272,4554 pr. aksje. Oversikt over transaksjoner: DatoHandels- plattformAggregert daglig volum (antall aksjer)Vektet gjennomsnittspris pr. aksje (NOK)Total transaksjonsverdi (NOK)11. marsOSE418.253270,5620113.163.368,20CEUX43.398271,319511.774.725,20TQEX13.349271,11583.619.124,7512. marsOSE460.000271,2967124.796.463,00CEUXTQEX13. marsOSE340.002272,555792.669.498,05CEUX74.4012

Aegon calls EUR 700 million of fixed-to-floating subordinated notes19.3.2024 08:00:00 CET | Press release

The Hague, March 19, 2024 - Aegon today announces it is exercising its right to redeem EUR 700 million of 4% fixed-to-floating subordinated notes. The redemption of these grandfathered Tier 2 securities will be effective as of April 25, 2024, when the aggregate principal amount of EUR 700 million will be repaid, together with any accrued and unpaid interest. As previously announced, Aegon intends to refinance the notes. The securities (ISIN code: XS1061711575) are currently listed on Euronext Amsterdam. This listing will be terminated following the redemption of the securities. A notice of redemption will be sent to all currently registered holders of the notes by the fiscal agent, Citibank N.A., London Branch. Contacts Media relationsInvestor relationsRichard MackillicanYves Cormier+31(0) 62 741 1546+31(0) 70 344 8028richard.mackillican@aegon.comyves.cormier@aegon.com About Aegon Aegon is an international financial services holding company. Aegon’s ambition is to build leading busines

Mendus to present NK cell program progress at the Innate Killer Summit19.3.2024 08:00:00 CET | Press release

Press Release Stockholm, Sweden, March 19, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will present the progress of its NK cell program at the 9th Annual Innate Killer Cell Summit, a leading conference for NK cell-based therapies. Mendus Director of Research Satwinder Kaur Singh, PhD will be expert speaker at the 9th Annual Innate Killer Summit held March 18-20 in San Diego, CA, USA. The Innate Killer Summit is a leading global conference dedicated to advancing NK cell therapies to clinic. This year’s theme of the conference is “Improve Functionality & Streamlining Manufacture to Realise the Potential of NK Therapies.” Dr Singh will present research data demonstrating the use of Mendus’ DCOne platform to expand so-called memory NK cells, their phenotypic and functional characterization and the steps taken by Mendus to develop a manufacturing process suitable for therapeutic purposes. The

HiddenA line styled icon from Orion Icon Library.Eye